|
|
|
|
||
Re: INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800Other than grants, no revenues except what they got from DoD, now cancelled. Kim's choice for the Phase III, Brazil etc., is a smart move as infrastructure outside of the big cities in those countries precludes the refrigeration needed by the other vaccines. Now lets see if INO can execute their plan and get approval in China too. To be more exact why are you invested in INO if not for future revenues? I was originally here for HPV and Glio, so for me the Covid vaccine is serendipitous. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
2132 | Re: INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800 | billmax | 0 | 8/27/2021 3:52:36 PM |